Posted in | News | Nanomedicine

Symposium Focuing on Nano-Drugs and Nanotechnology for Cancer Treatment

Recent years have witnessed the rapid development of China's nano-science and technology with widespread influence. On January 2008, a proposal to convene a Sino-US symposium on nano-medicine and nano-biology was jointly made by Director of the US National Institutes of Health Dr. Elias Zerhouni, Director of the US National Cancer Institute Dr. John E. Niederhuber and Director of the National Institute of Environmental Health Sciences Dr. Samuel Wilson. To integrate outstanding research forces in China and carry out exchanges with scholars of the world, in particular US, the Xiangshan Science Conferences (XSSC) was hold a symposium on nanotechnology and nano-drugs for cancer treatment from 21 to 23 October in Beijing.

Studies of nanotechnology and nano-drugs for cancer treatment are an emerging field that takes full advantage of expertise and research approaches from such academic disciplines as nanotechnology, biology, chemistry, physics, medicine, pharmaceutics and public health. No single discipline can deal with the new field characterized with strong interdisciplinary and comprehensive studies. It is both a topic at the cutting-edge of science development and an important social issue closely related to people's health and environment, offering unlimited opportunities for innovation.

The meeting was focused on nano-drugs and nano-technology for cancer treatment, environmental health of nanotechnology and its safety, and the strategy and policy for nanotechnology development.

Source: Chinese Academy of Sciences

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.